VIDEX
LOE ApproachingNDAORALTABLET, CHEWABLEPriority Review
Approved
Oct 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIDEX is an oral small-molecule antiretroviral approved in 1991 for HIV treatment. The drug is administered as a chewable tablet and represents an early nucleoside reverse transcriptase inhibitor (NRTI) class therapy. It is now approaching loss of exclusivity with significant competitive pressure in the HIV treatment landscape.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30/100) signals a transition from growth to maintenance phase, suggesting smaller team sizes and defensive positioning strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)
HIV Infections
Comparing Side Effects of Two Forms of Videx in HIV-Infected Adults
200 enrolled
HIV Infections
Career Relevance
Working on VIDEX offers experience in managing a legacy product through loss of exclusivity and competitive erosion, valuable for career development in market access and defensive brand strategy. This role is best suited for professionals seeking to understand mature product lifecycle management and generic transition planning rather than growth-phase innovation.
Worked on VIDEX at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.